1. Pathology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain;
2. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Madrid, Spain;
3. Lymphoma Unit, Department of Hematology, Fundación Jiménez Díaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain;
4. Lymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain;
5. Pathology Department, Hospital Universitario 12 de Octubre, Madrid, Spain;
6. Pathology Department, Hospital MD Anderson Cancer Center, Madrid, Spain;
7. Pathology Department, Hospital Virgen de la Salud, Toledo, Spain;
8. Pathology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain;
9. Pathology Department, Hospital Universitario Puerta de Hierro-Segovia de Arana, Madrid, Spain;
10. Pathology Department, Hospital Universitari de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain;
11. Haematology Department, Hospitalario Universitario de Salamanca (HUS/IBSAL), Salamanca, Spain;
12. Bioinformatics Unit, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain;
13. Department of Genetics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain;
14. Center for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain;
15. Kura Oncology Inc., San Diego, CA; and
16. UGC Laboratorios, Hospital Universitario de Puerto Real, Cádiz, Spain